



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification ⁷ : A61K 38/21, A61P 31/14 // (A61K 38/21, 31:365) (A61K 38/21, 31:4164) (A61K 38/21, 31:517) (A61K 38/21, 31:13) (A61K 38/21, 31:505) (A61K 38/21, 31:7052)</p>	A2	<p>(11) International Publication Number: WO 00/50064</p> <p>(43) International Publication Date: 31 August 2000 (31.08.00)</p>					
<p>(21) International Application Number: PCT/US00/04699</p> <p>(22) International Filing Date: 25 February 2000 (25.02.00)</p> <p>(30) Priority Data:</p> <table border="0"> <tr> <td>60/121,931</td> <td>26 February 1999 (26.02.99)</td> <td>US</td> </tr> <tr> <td>60/181,068</td> <td>8 February 2000 (08.02.00)</td> <td>US</td> </tr> </table> <p>(71) Applicant (for all designated States except US): INSTITUTE OF MOLECULAR AND CELL BIOLOGY [SG/SG]; 30 Medical Drive, Singapore 117609 (SG).</p> <p>(72) Inventors; and</p> <p>(75) Inventors/Applicants (for US only): TAN, Yin, Hwee [CA/SG]; 30 Medical Drive, Singapore 117609 (SG). DRISCOLL, John, S. [US/US]; 4 Infield Court South, Rockville, MD 20854 (US).</p> <p>(74) Agent: WILSON, Mary, J.; Nixon & Vanderhye P.C., Suite 800, 1100 North Glebe Road, Arlington, VA 22201-4714 (US).</p>	60/121,931	26 February 1999 (26.02.99)	US	60/181,068	8 February 2000 (08.02.00)	US	<p>(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p>Published Without international search report and to be republished upon receipt of that report.</p>
60/121,931	26 February 1999 (26.02.99)	US					
60/181,068	8 February 2000 (08.02.00)	US					
<p>(54) Title: SYNERGISTIC COMBINATION FOR TREATMENT OF VIRAL-MEDIATED DISEASES</p> <p>(57) Abstract</p> <p>Flavivirus and rhabdovirus infections may be treated by administering an interferon such as interferon $\alpha 2$, interferon $\alpha 8$ or interferon β and at least one compound selected from 5-membered cyclic nucleosides, mycophenolic compounds, imidazole derivatives, aminoadamantanes and 2, 4-diaminopyrimidines.</p>							

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

SYNERGISTIC COMBINATION FOR TREATMENT OF
VIRAL-MEDIATED DISEASES

Field of the Invention

5 This invention relates to the use of interferons as antiviral agents.

Background to the Invention

Human interferons (IFN) were originally prepared from human white blood cells, a by-product of blood banks, and from primary human fibroblasts in culture.

10 The white cell product was called human leukocyte interferon or human alpha interferon and the human fibroblast interferon was called human β interferon. Subsequent to the cloning of interferons in *E. coli*, several subtypes of human interferons have been identified. There are at least 15 subtypes of alpha interferon (Henco K. *et al.*, J. Mol Biol. 185, 227-260, 1985) and only one β interferon.

15 Cyclopentenyl cytosine (CPE-C) was a promising anti-tumor compound in clinical trial until two deaths were observed in the trial. Four of the eleven patients who received 4.7 mg/m² per hour of CPE-C experienced hypotension 24 to 48 hours after completion of the CPE-C infusion during their first, third and sixth cycles respectively. Two of the four hypotensive patients died with refractory hypotension.

20 The trial was immediately stopped by the National Cancer Institute, USA. Hypotension was not seen in patients receiving ≤ 2.5 mg/m² per h CPE-C (Cancer Chemother. Pharmacol. 36, 513-523, 1995). The mean CPE-C steady-state plasma levels (Cpss) increased linearly from 0.4 μ M to 3.1 μ M at doses ranging from 1 to 5.9 mg/m²/h.

25 Mycophenolic acid was first demonstrated by H. Florey in 1946 to inhibit bacteria, fungi and leukocytes. The prodrug mycophenolate mofetil is now an FDA-approved transplantation drug.

Summary of the Invention


30 We have now found that an interferon such as interferon $\alpha 2$, interferon $\alpha 8$ or interferon β can act synergistically with particular compounds to combat flavivirus

-2-


and rhabdovirus infections. This synergistic antiviral effect means that lower concentrations of the small molecular weight chemicals such as CPE-C can be used together with interferons as ant Flaviviral and antirhabdoviral agents and at concentrations below its anticipated side effects (hypotension) in man (1.0 μ M or less).

Accordingly, the present invention provides a method of treating a host having a flavivirus or rhabdovirus infection, which method comprises the step of administering to the host in respective amounts which produce a synergistic ant Flaviviral or synergistic antirhabdoviral effect:

- (a) an interferon, and
- (b) at least one compound selected from the group consisting of:
 - 5-membered cyclic nucleosides having the formula (I):



- wherein $\sim X \sim$ is $=CH-$, $-CH_2-$ or $-O-$, Nu is selected from the group consisting of purines, pyrimidines and five- or six-membered aglycones, R_2 and R_3 are independently selected from the group consisting of H, OH, O-acyl, O-aryl and O-silyl, and R_1 is as defined for R_2 and R_3 or is O-phosphate, and pharmaceutically acceptable metabolites, metabolite derivatives and salts thereof;
- mycophenolic acid compounds having the formula (II)




-3-


wherein R_4 is $-OR_6$ or $-N(R_7)R_8$ in which R_6 , R_7 and R_8 are independently selected from the group consisting of hydrogen and C_1 - C_6 alkyl, and R_5 is selected from the group consisting of hydrogen, phenyl and C_1 - C_6 alkyl unsubstituted or substituted by a five- or six-membered saturated or unsaturated heterocyclic ring, and

5 pharmaceutically acceptable salts thereof;

- imidazole derivatives represented by formula (III):




wherein R_9 is a hydrogen atom or



wherein R_{10} is a hydrogen atom, C_1 - C_6 alkyl, hydroxy(C_1 - C_6 alkyl) or phenyl, R_{11} and R_{13} are independently selected from hydrogen and OR_{12} , R_{12} is a hydrogen atom or a hydroxy protecting group and A is $CONH_2$ or CN, and

20 pharmaceutically acceptable salts thereof;

- aminoadamantanes having the formula (IV):



wherein each of R_{14} , R_{15} , R_{16} and R_{17} is independently selected from the group consisting of H, F and CH_3 and X is $N(R_{18})_2$, $CH_2CH_2N(R_{18})_2$ or $C(R_{19})_2N(R_{18})_2$ wherein each R_{18} and R_{19} is H, (C_1 - C_6) alkyl, (C_6 - C_{10}) aryl and


30

-4-

(C₇-C₁₈) aralkyl; and

- 2,4-diaminopyrimidines having the formula (V):


5



10

wherein R₂₀ is phenyl substituted by one or more substituents selected from the group consisting of aralkyl, NO₂, (C₁-C₆) alkylamino and halogen and R₂₁ is H or C₁-C₆ alkyl; or R₂₀ and R₂₁ form, together with the 2,4-diaminopyrimidine ring to which they are attached, a quinazoline derivative of formula (V'):

15



20

wherein Z is -CH₂NR₂₃- or -NR₂₃CH₂-; R₂₂, R₂₃ and R₂₄ are each, independently, H or C₁-C₆ alkyl; and n is 1 or 2, and pharmaceutically acceptable salts thereof.

In formula (V) the aralkyl substituent is an aryl group linked via an alkylene chain of 1 to 6 carbon atoms. Aryl is typically phenyl or naphthyl. Preferred examples of aralkyl are benzyl and phenethyl. In formula (V') R₂₂ is preferably methyl or ethyl, especially ethyl, R₂₃ and R₂₄ are preferably H and n is preferably 1.

The present invention encompasses all optical isomers of the compound (b), in particular the D- and L-isomers of the nucleosides of formula (I) and of the quinazoline derivatives of formula (V').

-5-

rhabdovirus infections also forms part of the invention. The invention therefore further provides a method of treating a host having a flavivirus or rhabdovirus infection, which method comprises the step of administering to the host a therapeutically effective amount of an interferon $\alpha 8$ having a specific activity of from

5 0.3x10⁹ to 3x10⁹ IU per mg protein.

The invention additionally provides:

- use of an interferon in the manufacture of a medicament for use with at least one compound (b) as defined above in the treatment of a flavivirus or rhabdovirus infection;
- 10 - use of at least one compound (b) as defined above in the manufacture of a medicament for use with an interferon in the treatment of a flavivirus or rhabdovirus infection;
- products containing an interferon and at least one compound (b) as defined above as a combined preparation for simultaneous, separate or sequential use
- 15 in treating a flavivirus or rhabdovirus infection;
- interferon $\alpha 8$ having a specific activity of from 0.3x10⁹ to 3x10⁹ IU per mg of protein for use in a method of treatment of the human or animal body by therapy;
- use of interferon $\alpha 8$ having a specific activity of from 0.3x10⁹ to 3x10⁹ IU per
- 20 mg of protein in the manufacture of a medicament for use in the treatment of a flavivirus or rhabdovirus infection; and
- an anti-flavivirus or anti-rhabdovirus agent comprising interferon $\alpha 8$ having a specific activity of from 0.3x10⁹ to 3x10⁹ IU per mg of protein.

25 **Detailed Description of the Invention**

Interferons

The interferon for use in the present invention may be an interferon α , such as interferon $\alpha 2$ or $\alpha 8$, or interferon β . The term "interferon" includes fragments which have interferon activity and mutant forms of an interferon which retain interferon

30 activity. For example, the sequence of an interferon α or β may have been modified to enhance activity or stability as reported in US-A-5582824, US-A-5593667 or US-

A-5594107.

The interferon may have been purified from natural sources or may be a recombinant interferon. The species of interferon is generally the same as the host species to which the interferon is administered. The invention is particularly
5 applicable to the treatment of flavivirus infections in humans. Preferably therefore a human interferon such as human interferon $\alpha 2$ or $\alpha 8$ or human interferon β is used.

The interferon $\alpha 8$, particularly the human interferon $\alpha 8$, typically has a specific activity of more than 0.6×10^9 , generally from 0.6×10^9 to 1.5×10^9 and preferably from 0.8×10^9 to 1.5×10^9 , IU per mg protein. The human interferon β
10 typically has a specific activity of from 4×10^8 to 8×10^8 , preferably from 4.8×10^8 to 6.4×10^8 , IU per mg protein. Interferon α and interferon β specific activities are determined according to reference standards Gb-23-902-530 and Gb-23-902-531 respectively. Specific activity is determined according to a modification of the method of Armstrong, Applied Microbiology 21, 723, 1971, in which $0.2 \mu\text{g/ml}$ of
15 actinomycin D is included in the viral challenge and the viral induced cytopathic effect (CPE) is read directly from the primary human fibroblasts. Alternatively, specific activity is determined according to the method of Armstrong using WISH cells as assay cells and Encephalomyocarditis virus as challenge virus and the viral induced CPE is read directly.

20 The interferon such as the interferon $\alpha 2$ or $\alpha 8$ or the interferon β is preferably obtainable by the methodology of WO 96/30531. The interferon is thus obtainable by a process comprising culturing mammalian cells transfected with a nucleic acid vector comprising:

- (i) a coding sequence which encodes the interferon and which is operably linked
25 to a promoter capable of directing expression of the coding sequence in mammalian cells in the presence of a heavy metal ion;
- (ii) a first selectable marker sequence which comprises a metallothionein gene and which is operably linked to a promoter capable of directing expression of the metallothionein gene in the cells in the presence of a heavy metal ion; and
- 30 (iii) a second selectable marker sequence which comprises a *neo* gene and which is operably linked to a promoter capable of directing expression of the *neo*

-7-

gene in the cells;
unless conditions that allow expression of the coding sequence; and recovering the
interferon thus produced.

The transfected mammalian cells may be cells of a human or animal cell line.
5 They may be BHK, COS, CHO Lec2, L CL3, Vero, human fibroblastoid such as
C10, HeLa, or human lymphoblastoid cells or cells of a human tumour cell line.
Preferably, however, the cells are CHO cells, particularly wild-type CHO cells.

Desirably, transfected cells will have all or part of such a vector integrated
into their genomes. Such cells are preferred because they give stable expression of
10 the coding sequence contained in the vector. Preferably, one or more copies of the
entire vector will be integrated, with cells having multiple integrated copies of the
vector, for example from 20 to 100 copies or more, being particularly preferred
because these cells give a high stable level of expression of the coding sequence
contained in the vector.

15 However, cells having less than complete sections of the vectors integrated
into their genomes can be employed if they are functionally equivalent to cells
having the entire vector integrated into their genomes, in the sense that the integrated
sections of the vector enable the cell to express the coding sequence and to be
selected for by the use of heavy metals. Thus, cells exhibiting partial integration of a
20 vector may be employed if the integrated element or elements include the coding
sequence operably linked to its associated promoter and the metallothionein marker
sequence operably linked to its associated promoter.

Any promoter capable of enhancing expression in a mammalian cell in the
presence of a heavy metal ion such as Cd^{2+} , Cu^{2+} and Zn^{2+} may be operably linked to
25 the interferon coding sequence. A suitable promoter is a metallothionein gene
promoter. The mouse metallothionein gene I (mMT1) promoter is preferred.

Suitable promoter/enhancer combinations for the coding sequence include the
mMT1 promoter flanked upstream with a mouse sarcoma virus (MSV) enhancer
(MSV-mMT1) and a Rous sarcoma virus (RSV) enhancer upstream of a mouse
30 mammary tumour virus (MMTV) promoter. MSV-mMT1 is preferred.

As far as the first selectable marker sequence is concerned, any promoter

-8-

capable of enhancing expression in a mammalian cell in the presence of a heavy metal ion such as Cd^{2+} , Cu^{2+} and Zn^{2+} may be operably linked to the metallothionein gene such as a human metallothionein gene. Preferably, the marker sequence gene is a human metallothionein gene, such as the human metallothionein gene IIA, which
5 has its own promoter.

The second selectable marker sequence is a *neo* gene. More than one type of this gene exists in nature: any specific *neo* gene can be used in a vector of the invention. One preferred *neo* gene is the *E.coli neo* gene.

The promoter for the *neo* gene is capable of directing expression of the gene
10 in a mammalian cell. Suitable promoters are the cytomegalovirus (CMV) early promoter, the SV40 promoter, the mouse mammary tumour virus promoter, the human elongation factor 1 α -P promoter (EF-1 α -P), the SR α promoter and a metallothionein gene promoter such as mMT1. The promoter may also be capable of expressing the *neo* gene in bacteria such as *E.coli* in which a vector may be
15 constructed.

The interferon coding sequence (i) and the marker sequences (ii) and (iii) are thus each operably linked to a promoter capable of directing expression of the relevant sequence. The term "operably linked" refers to a juxtaposition wherein the promoter and the coding/marker sequence are in a relationship permitting the
20 coding/marker sequence to be expressed under the control of the promoter. Thus, there may be elements such as 5' non-coding sequence between the promoter and coding/marker sequence. Such sequences can be included in the construct if they enhance or do not impair the correct control of the coding/marker sequence by the promoter.

25 The vector may be a DNA or RNA vector, preferably a DNA vector. Typically, the vector is a plasmid. Each of the sequences (i) to (iii) will typically be associated with other elements that control their expression. In relation to each sequence, the following elements are generally present, usually in a 5' to 3' arrangement: a promoter for directing expression of the sequence and optionally a
30 regulator of the promoter, a translational start codon, the coding/marker sequence, a polyadenylation signal and a transcriptional terminator.

Further, the vector typically comprises one or more origins of replication, for example a bacterial origin of replication, such as the pBR322 origin, that allows replication in bacterial cells. Alternatively or additionally, one or more eukaryotic origins of replication may be included in the vector so that replication is possible in, for example yeast cells and/or mammalian cells.

The vector may also comprise one or more introns or other non-coding sequences 3' or 5' to the coding sequence or to one or more of the marker sequences. Such non-coding sequences may be derived from any organism, or may be synthetic in nature. Thus, they may have any sequence. Such sequences may be included if they enhance or do not impair correct expression of the coding sequence or marker sequences.

The transfected cells are typically cultured in the presence of a heavy metal ion selected from Cd^{2+} , Cu^{2+} and Zn^{2+} , particularly in an amount which is not toxic to the cells. That can lead to higher expression of the desired interferon. The concentration of the heavy metal ion in the culture medium is typically from 100 to 200 μM . Cells may therefore be cultured in the presence of from 100 to 200 μM of a heavy metal ion selected from Cd^{2+} , Cu^{2+} and Zn^{2+} , for example from 130 to 170 μM of the heavy metal ion. A useful concentration is about 150 μM , particularly when the heavy metal ion is Zn^{2+} .

The interferon that is produced may be recovered by any suitable means and the method of recovery may vary depending on, for example, the type of cells employed and the culture conditions that have been used. Desirably, the interferon produced will be purified after recovery. Substantially pure interferon can thus be obtained.

The human β -interferon provided by WO 96/30531 has a high degree of sialylation. Like natural human β -interferon produced by primary diploid human fibroblasts, it is well glycosylated. However, it has a higher bioavailability than the natural β -interferon or recombinant β -interferon produced in *E.coli* (betaseron).

The higher bioavailability of the β -interferon can be characterised. When 1.5×10^6 IU of the interferon is injected subcutaneously into the back of a rabbit of about 2 kg: (a) ≥ 128 IU/ml of the interferon is detectable in the serum of the rabbit after 1

hour, and/or (b) ≥ 64 IU/ml of the interferon is detectable in the serum of the rabbit after 5 hours.

The maximum level of interferon is typically observed after 1 hour.

According to (a), therefore, 128 to 256 IU/ml such as 140 to 190 IU/ml of the
5 interferon may be detectable in the rabbit serum after 1 hour. After 5 hours according to (b), ≥ 70 IU/ml such as ≥ 80 IU/ml of the interferon may be detectable in the rabbit serum. Typically according to (b), an amount of interferon in the range of 64 to 128 IU/ml such as 80 to 110 IU/ml can be detected.

Additionally or alternatively, the human interferon β can be characterised by
10 its specific activity. It can have a specific activity from 4.8×10^8 to 6.4×10^8 IU per mg equivalent of bovine serum albumin protein, as noted above. The specific activity may be from 5×10^8 to 6×10^8 , for example from 5.2×10^8 to 5.8×10^8 such as from 5.3×10^8 to 5.5×10^8 , IU per mg equivalent of bovine serum albumin protein.

15 The human interferon β may also be characterised by one or more of the following properties:

1. The interferon β typically has an apparent molecular weight of 26,300 as determined by 15% sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE).
- 20 2. When injected as a neat intravenous bolus into a rabbit, the half life of the interferon is typically in the range of from 12 to 15 min such as about $13\frac{1}{2}$ min. The bolus is injected into the rabbit ear vein and blood samples are withdrawn from the rabbit ear artery. Rabbit serum is assayed for the antiviral activity of the interferon according to the modification of the method
25 of Armstrong (1971).
3. The antiviral activity of the interferon in a human hepatoblastoma cell line (HepG2) is at least equal to and, typically, about 1.5 times the activity of natural interferon β from primary diploid human fibroblast cells. The interferon is also about 2.2 times more effective than betaseron in protecting
30 Hep2 cells against a viral challenge. Antiviral activity is again determined according to the modified method of Armstrong (1971). Actinomycin D was

-11-

omitted in the antiviral determination in HepG2 cells.

The oligosaccharides associated with the interferon β of the invention may also characterise the interferon β . The interferon β carries oligosaccharides which can be characterised by one or more of the following features:

1. Neutral (no acidic substituents): 5 to 15%, preferably about 10% or lower.
Acidic : 95 to 85%, preferably about 90% or higher.
2. The total desialylated oligosaccharide pool is heterogeneous with at least six distinct structural components present in the pool.
3. Matrix-Assisted Laser Desorption Ionisation - Time of Flight (MALDI-TOF) mass spectrometry and high resolution gel permeation chromatography data are summarised as follows:

Mass detected	Composition	Calculated Mass	gu equivalent
1786.2	5Hex, 4HexNAc, 1 2AB, Na	1782	11.1
1929.9	5Hex, 1dHex, 4HexNAc, 1 2AB, Na	1928	12.2
2295.5	6Hex, 1dHex, 5HexNAc 1 2AB, Na	2293	14.5
2660.1	7Hex, 1dHex, 6HexNAc 1 2AB, Na	2658	17.6
3019.1	8Hex, 1dHex, 7HexNAc, 1 2AB, Na	3023	20.7

The carbohydrate moiety of the human interferon β of WO 96/30531 consists of bi-, tri- and tetra-antennary complex type N-linked oligosaccharides. These oligosaccharides contain repeating lactosamine(s). About 20 to 50%, for example 20 to 30%, 30 to 40% or 35 to 50%, of the oligosaccharides are bi-antennary

-12-


oligosaccharides. About 30 to 65%, for example from 40 to 60% or 50 to 60%, of the oligosaccharides are tri-antennary oligosaccharides. About 2 to 15%, for example from 2 to 8%, 4 to 10% or 5 to 15%, of the oligosaccharides are tetra-antennary oligosaccharides. Percentages are calculated by weight of total analysable oligosaccharide content.

Compounds (b)

The compounds (b) are capable of inhibiting particular enzymes. Amongst the 5-membered cyclic nucleosides of formula (I), some of those in which $\sim X \sim$ is -O-, such as pyrazofurin and 6-azauridine, are inhibitors of orotidylate decarboxylase whilst tiazofurin and selenofurin are inhibitors of inositol monophosphate dehydrogenase (IMPH). Compounds of formula (I) in which $\sim X \sim$ is =CH- are typically inhibitors of cytosine triphosphate (CTP) synthetase and S-adenosylhomocysteine hydrolase.

The mycophenolic acid compounds of formula (II) and the imidazole derivatives of formula (III) are typically inhibitors of inosine monophosphate (IMP) dehydrogenase. The aminoadamantanes of formula (IV) inhibit the uncoating of influenza viruses. The 2,4-diaminopyrimidines of formula (V) and the quinazoline derivatives of formula (V') are inhibitors of dihydrofolate reductase.

In one embodiment the 5-membered cyclic nucleosides of formula (I) are cyclopentenyl carbocyclic nucleosides in which $\sim X \sim$ is =CH-. These have the following structure (I'):




wherein R_1 , R_2 , R_3 and Nu are as defined above for formula (I).

Preferred 5-membered cyclic nucleosides of formula (I) and cyclopentenyl carbocyclic nucleosides of formula (I') are compounds in which Nu denotes one of

-13-

the following groups (i) to (viii):




20

wherein R_{25} is Cl or NH_2 and R_{26} is H, CH_3 , CF_3 , F, Cl, Br or I.

When one or more of R_1 , R_2 and R_3 is O-acyl in formula (I) or (I'), the acyl group is preferably a group having the formula $R_{27}-CO-$ in which R_{27} is C_1-C_6 alkyl such as C_1-C_4 alkyl, for example methyl or ethyl. The O-aryl group is generally a O-
 25 (C_6-C_{10}) aryl group such as O-phenyl or O-benzyl. R_2 and R_3 may together denote a ketal group such as

30



The 5-membered cyclic nucleosides of formula (I) are known compounds and

may be synthesised by published procedures or by analogy with published procedures. For instance the synthesis of carbocyclic adenosine [(±)-aristeromycin] is described by Shealy *et al* in J. Am Chem. Soc. 1966, 88, 3885 and in J. Am. Chem. Soc. 1969, 91, 3075. The enantioselective synthesis of (-) aristeromycin and (-)-neplanocin A is described by Arita *et al* in J. Am. Chem. Soc. (1983), 105 (12), 4049-4055.

The synthesis of pyrazofurin is described by Petrie *et al* in J. Med. Chem 1986, 29, 268-278. The synthesis of 6-azauridine is described by Cristescu in Rev. Roum. Chim (1968), 13(3), 365-9. The synthesis of tiazofurin (2-β-D-ribofuranosylthiazole-4-carboxamide) and selenofurin (2-β-D-ribofuranosylselenazole-4-carboxamide) is described by Hennen *et al* in J. Org. Chem (1985) 50(10), 1741-1746. The synthesis of suitable cyclopentenyl carbocyclic nucleosides of formula (I') is described in US-A-4975434, the contents of which are incorporated herein by reference. Specific nucleosides are listed in that patent.

The substitution patterns of preferred compounds of formula (I) are shown in Table 1 below. A particularly preferred compound is cyclopentenyl cytosine (CPE-C).

Table 1: Substitution patterns within formula (I)

$\sim X \sim$	R ₁	R ₂	R ₃	formula of Nu	Compound
=CH -	OH	OH	OH	(ii) wherein R ₂₅ is NH ₂	3-deazaneplanocin
=CH-	OH	OH	OH	(i) wherein R ₂₅ is NH ₂	neplanocin A
-O-	OH	OH	OH	(vi)	3-deazauridine
-O-	OH	OH	OH	(iv)	6-azauridine (NSC 32074)

-CH ₂ -	OH	OH	OH	(i) wherein R ₂₅ is NH ₂	aristeromycin (NSC 103526)
-O-	OH	OH	OH	(v)	pyrazofurin (NSC 143095)
=CH-	OH	OH	OH	(iii) wherein R ₂₆ is H	cyclopentenylcytosine (CPE-C)
-O-	OH	OH	OH	(vii)	tiazofurin (NSC 286193)
-O-	OH	OH	OH	(viii)	selenofurin (NSC 340847)

As used herein the term "metabolite" refers to a compound for which a compound of formula (I) is a prodrug. For instance, tiazofurin and selenofurin are prodrugs for thiazolamide adenine dinucleotide (TAD) and selenazolamide adenine dinucleotide (SAD), respectively. In each case the metabolite, rather than the
5 prodrug, is the active moiety. Examples of derivatives (or analogues) of these particular metabolites, which are also encompassed within the present invention, include beta-methylene TAD and beta-methylene SAD. These compounds are published in the literature.

The mycophenolic acid compounds of formula (II) include compounds in
10 which R₄ is hydroxy or NH₂. When one or more of R₅, R₆, R₇ and R₈ is a C₁-C₆ alkyl group, preferably it is a C₁-C₄ alkyl group such as methyl or ethyl. The five- or six-membered saturated or unsaturated heterocyclic ring generally contains one, two or three N-atoms and optionally an O- and/or S-atom. Suitable such rings include pyridino, piperidino, pyrrolo, pyrrolidono and morpholino rings. A N-morpholino
15 ring may thus be present.

Mycophenolic acid compounds for use in the invention include mycophenolic acid, mycophenolate mofetil which is the morpholinoethyl ester of mycophenolic acid, and the individual mycophenolic acid derivatives described in US-A-5380879. The contents of US-A-5380879 are incorporated herein by reference.



Suitable imidazole derivatives of formula (III) are compounds wherein R_{10} is hydrogen, C_1 - C_4 alkyl such as methyl or ethyl, hydroxy(C_1 - C_4 alkyl) in which the alkyl group may be methyl or ethyl, or phenyl. R_{12} may be hydrogen or any appropriate protecting group such as an acyl, alkyloxymethyl, substituted ethyl, aralkyl, pyranyl, silyl, acetal or ketal group. Typically, R_{11} and/or R_{13} is H or OH.

Imidazole derivatives of formula (III) are described in US-A-5126361, the contents of which are incorporated herein by reference. A particularly preferred imidazole derivative is 5-ethynyl-1- β -D-ribofuranosyl-imidazole-4-carboxamide (EICAR). EICAR is a compound of formula (III) in which A is $CONH_2$, R_9 is D-ribose and R_{10} is hydrogen.



Aminoadamantanes of formula (IV) are described in US-A-5599998, the contents of which are incorporated herein by reference. In formula (IV), R_{18} and R_{19} may each independently denote hydrogen, C_1 - C_4 alkyl such as methyl or ethyl, phenyl or benzyl. Suitable compounds include 1-aminoadamantane ("amantidine"), α -methyl-1-adamantylmethylamine ("rimantidine") and 1-amino-3,5-dimethyladamantane ("momantine").

The synthesis of 2,4-diaminopyrimidines of formula (V) is described by D. J. Brown in the chapter "Pyrimidines and their Benzo Derivatives" in Comprehensive Heterocyclic Chemistry, Vol. 3, part 2B, A. Boulton and A. McKillop (Eds), 1983, Pergamon, Oxford, page 151, the contents of which are incorporated herein by reference. The substitution patterns of preferred compounds of formula (V) are shown in Table 2 below:

Table 2: Substitution patterns within formula (V)

R_{20}	R_{21}	Compound
	$-CH_2CH_3$	NSC 382046
	$-CH_3$	NSC 7364

-17-

	-CH ₂ CH ₃	NSC 302325
	-CH ₂ CH ₃	NSC 382034

5 The quinazoline derivatives of formula (V') may be synthesised as described by Hynes *et al* in J.Med. Chem., 1977, Vol 20, No. 4, 588-591 or by analogy with the methods described there. A preferred quinazoline derivative of formula (V') is the compound wherein R₂₂ is C₂H₅, R₂₃ and R₂₄ are both H and n is 1. This is known as NSC 184692.

10 Pharmaceutically acceptable salts, particularly pharmaceutically acceptable acid addition salts, of any of the compounds of formula (I) to (IV) may be used. Salts with physiologically acceptable inorganic or organic acids may be employed, for example the hydrochloride salt.

15 Therapeutic uses

The interferons and compounds (b) are used together to treat flavivirus and rhabdovirus infections, particularly in humans. The infection may be acute or chronic. The flavivirus may be yellow fever virus, kunjin virus, dengue virus, hepatitis C virus, or an encephalitis virus such as St. Louis encephalitis virus,

20 Japanese encephalitis virus, Murray valley encephalitis virus and tick-borne

encephalitis virus. The rhabdovirus may be vesicular stomatitis virus (VSV) or rabies virus.

The interferon and at least one compound (b) are administered to a subject to be treated in sufficient amounts to produce a synergistic antiviral or synergistic antirhabdoviral effect. The condition of the subject can thus be improved. The infection may be cleared from the subject entirely. Relative to monotherapy, lower doses of the interferon and of the compound(s) (b) can be used, which results in a cost-saving and a reduction or elimination of side effects that might occur at higher doses.

10 Separate formulations of the interferon on the one hand and of the compound(s) (b) on the other hand will generally be given to a patient. A single formulation containing both components can be administered if the interferon and compound(s) (b) are stable in each other's presence and do not otherwise interfere with each other.

15 The interferon may be administered to humans in various manners such as orally, intravenously, intramuscularly, intraperitoneally, intranasally, intradermally, topically and subcutaneously. The particular mode of administration and dosage regimen will be selected by the attending physician taking into account a number of factors including the age, weight and condition of the patient, the nature of the viral
20 infection, the compound(s) (b) with which it is being administered and the need to obtain a synergistic effect.

The pharmaceutical compositions that contain the interferon as an active principal will normally be formulated with an appropriate pharmaceutically acceptable carrier or diluent depending upon the particular mode of administration
25 being used. For instance, parenteral formulations are usually injectable fluids that use pharmaceutically and physiologically acceptable fluids such as physiological saline, balanced salt solutions, or the like as a vehicle. Oral formulations, on the other hand, may be solids, e.g. tablets or capsules, or liquid solutions or suspensions.

The interferon will usually be formulated as a unit dosage form that contains
30 from 10^4 to 10^9 , more usually 10^6 to 10^7 , IU per dose. Typically from 3×10^6 to 18×10^6 IU of interferon is administered per day, particularly by injection such as

intravenously or subcutaneously. The dosage may be administered daily, for example for up to five or up to twenty weeks.

The compound(s) (b) can similarly be administered in a variety of dosage forms, for example orally such as in the form of tablets, capsules, sugar- or film-coated tablets, liquid solutions or suspensions, topically such as in the form of
5 creams, ointments or gels, or parenterally, for example intramuscularly, intravenously or subcutaneously. They may therefore be given by injection or infusion.

The mode of administration and dosage regimen of the compound(s) (b) also depends on a variety of factors including the particular compound(s) (b) concerned,
10 the age, weight and condition of the patient, the nature of the viral infection and the need to obtain a synergistic effect. Typically, however, the dosage adopted for each route of administration for humans, for example adult humans, is 0.001 to 10 mg/kg, most commonly in the range of 0.01 to 5 mg/kg, body weight. Such a dosage may be given, for example, daily. The dosage may be given orally or by bolus infusion,
15 infusion over several hours and/or repeated administration.

The interferon and the compound(s) (b) may be given simultaneously. Alternatively they may be given up to five days from each other, for example up to two days apart or up to one day apart or up to four hours apart. The relative timing of the administration of the interferon and the compound(s) (b) may be determined by
20 monitoring their respective serum levels. The interferon may be given before the compound(s) (b) or *vice versa*. Two or three compound(s) (b) may be given, for example simultaneously or spaced apart timewise as above.

A suitable treatment regiment may be illustrated with reference to CPE-C. As noted previously, two patients treated with CPE-C died in a clinical trial as a result of
25 hypotension. At dosages ≤ 2.5 mg/m²/h no hypotension was observed. Consequently, interferon $\alpha 8$ or interferon β must be used with CPE-C at dosages of CPE-C below which substantial hypotension occurs.

This may be achieved according to the invention by subcutaneous or intravenous injection of from 0.01 to 2.5 mg of CPE-C/m²/h and from 3 to 18, for
30 example 3, 6, 12 or 18, $\times 10^6$ IU of interferon on day 1. The CPE-C may be injected simultaneously with the interferon. Alternatively, the interferon may be injected up

-20-

to 4 hours later, for example from 1 to 4 hours later. On days 2 and 3, 3 to 18×10^6 IU of the interferon may be given to the patient. On day 4, the combination treatment of CPE-C and interferon can be repeated. This regimen may be repeated for several weeks, for example up to five or up to twenty weeks.

5

The following Examples illustrate the invention.

10 Example 1

Vero cells were grown to about 99% confluency in 96 microwells with minimum essential medium (MEM) containing 10% fetal calf serum. Growth medium was removed from the microwells and incubated with one of the following. The experiment was done in quadruplicates or duplicates:-

15

- (1) 100 μ l of interferon $\alpha 8$ containing either 6, 3, 0.6, 0.3, 0.06, or 0.03 IU of interferon (Reference to Gb 23-902-531, NIH standard, distributed by the Natl. Inst. Allergy and Infectious Diseases, NIH, USA) per ml of MEM containing 2.5 mg/ml human serum albumin.
- 20 (2) 100 μ l of interferon $\alpha 2$ containing either 6, 3, 0.6, 0.3, 0.06 or 0.03 IU of interferon (Reference to Gb-23-902-530 as well as Gb-23-902-531 standards) per ml of MEM containing 2.5 mg/ml human serum albumin.
- (3) 100 μ l of interferon β containing 60, 30, 6, 3 or 0.6 IU of interferon (Reference to Gb23-902-531 standard) per ml of MEM containing 2.5 mg/ml human
- 25 serum albumin.

After the addition of interferon to the Vero cells in the microwell, 100 μ l of a viral challenge consisting of 100 TCID₅₀ yellow fever virus, kunjin virus or dengue virus was added immediately to each of the microwells. Different concentrations of

30 test compound were included in the viral challenge as well. In the case where no test compound was used (i.e. the viral control), only 100 μ l of the viral challenge was

-21-

added to the wells in 100 μ l of MEM containing 2.5 mg/ml human serum albumin.

The test compounds used were cyclopentenyl cytosine (CPE-C) from the National Cancer Institute, USA; mycophenolic acid from Sigma Chemicals; 5-ethynyl-1- β -D-ribofuranosylimidazole-4-carboxamide (EICAR); and amantadine
5 hydrochloride.

In the control cells treated with test compound alone, 100 μ l of MEM containing 2.5 mg/ml human serum albumin instead of interferon was added to the cells followed by an addition of another 100 μ l of MEM/human serum albumin (2.5 mg/ml) containing test compound. In the case of CPE-C, the concentrations of CPE-
10 C in MEM were 2 μ M, 0.22 μ M and 0.022 μ M. The subsequent concentrations of CPE-C in the wells were therefore 1 μ M, 0.11 μ M and 0.011 μ M.

The cells were examined for virus-induced cythopathic effects on day 5, day 8 and day 9 respectively for the antiviral activities of interferon or of test compound(s) or of interferon and test compound(s) protecting against a challenge virus of yellow
15 fever, kunjin or dengue virus. The results of the enhancement of the antiviral effect of interferon by CPE-C is given in Table 3.

Table 3

20	Human interferon	μ M CPE-C	Fold enhancement of antiviral activity interferon
	α 8	1	30
	α 8	0.11	10
	α 8	0.01	0
	None	1*	0
25	None	0.11**	0
	None	0.011#	0
	α 2	1	10
	α 2	0.11	5
	α 2	0.01	0
30	None	1*	0
	None	0.11**	0
	None	0.011#	0

-22-

5	β	1	10
	β	0.11	5
	β	0.01	0
	None	1*	0
	None	0.11**	0
	None	0.011#	0

* 75-90% of the Vero cells were protected against a yellow fever virus challenge of 100 TCLD₅₀

10 ** 40-50% of the Vero cells were protected against a yellow fever virus challenge of 100 TCLD₅₀.

none of the Vero cells were protected against a yellow fever virus challenge of 100 TCLD₅₀ at this concentration of CPE-C.

15 Similar results in enhancement of the antiviral activity of interferon were observed when a viral challenge of 100 TCLD₅₀ of kunjin virus (0.11 μ M of CPE-C enhanced interferon α 8, interferon α 2 and interferon β by 10-, 5- and 5-fold respectively) or dengue virus (0.11 μ M of CPE-C enhanced interferon α 8, interferon α 2 and interferon β by 12-, 5- and 6-fold respectively) was used in place of yellow
20 fever virus.

Similar experiments were repeated with mycophenolic acid, amantadine hydrochloride and EICAR. The concentration required to enhance the anti-viral activity of human interferon α 8 is summarized in Table 4.

25

30

-23-

Table 4

Human interferon	μ M of test compounds #	Fold enhancement of antiviral activity
α 8	0.1 CPE-C(C)	10
α 8	0.1 mycophenolic acid	3
α 8	(MA)	3
α 8	1.0 EICAR (E)	2
α 8	1.0 amantadine (A)	50

Indicates the concentration of test compound alone to protect Vero cells against a viral challenge by approximately 50%. In the case of mycophenolic acid, 2% fetal calf serum was used in place of human serum albumin.

15 Example 2

Monkey (Vero) or human (HuH7) cells were grown on 96 microwells as described in Example 1. When the cells were grown to 90-100% confluency with growth medium (MEM or DMEM) containing 5 or 10% fetal calf serum, the growth medium was removed from the microwells and the cells re-incubated with one of the following. The experiment was done in quadruplicates or duplicates:-

100 μ l of human interferon α 8, α 2 or β interferon serially diluted from 30, 10, 3.3, 1.0, 0.33, 0.1, 0.033, 0.01, etc (Reference to Gb 23-902-531, NIH standard, distributed by the Natl. Inst. Allergy and Infectious Diseases, NIH, USA). In certain experiments using human cells, a serial 2-fold dilution of the interferon was used instead of the 30, 10, 3.3, 1.0, etc, dilution steps.

After adding the different concentrations of interferon to the cells in the microwells, 100 μ l of a viral challenge (yellow fever, dengue, kunjin virus or VSV) was immediately added to the microwells of cells previously treated with interferon and such that the viral challenge has a final TCID₅₀ of 100. Different concentrations of test compounds were added in the viral challenge. In the case where no test

-24-

compound was used (viral control) 100 µl viral challenge was added to the wells in 100 µl of MEM containing 2.5 mg/ml human serum albumin. The interferon control cells were challenged with virus without test compound. The test compound controls were challenged with virus but no interferon. The test compounds used were

5 cyclopentenyl cytosine (CPE-C) from the National Cancer Institute, USA; mycophenolic acid from Sigma Aldrich Inc.; 5-ethynyl-1-β-D-ribofuranosylimidazole-4-carboxamide (EICAR); amantadine hydrochloride; neplanocin A (provided by NCI, U.S.A.); 3-deazaneplanocin A (provided by NCI, USA); 3-deazauridine (Aldrich Chemical Co Inc.); NSC 382046, NSC 143095 and

10 Artisteromycin (Sigma Aldrich Inc).

The cells were examined for virus-induced cytopathic effects on days 1, 2, 3, 4, 5, 6, 7 and 8, depending on the virus used for the antiviral activities of interferon or of test compound(s) or of interferon and test compound(s) protecting against a challenge virus of either yellow fever, dengue, kunjin virus or VSV. The results of

15 the enhancement of the antiviral effect of the interferon used by each of the above test compounds are shown in the following Tables 5 to 22.

In the tables the IC₅₀ values represent the concentration of each agent required to give a 50% inhibition of cell death following viral challenge. Where an IC₅₀ value is shown as zero for one agent, that agent was not present. In those cases the IC₅₀

20 given for the other agent is the ED₅₀ of the latter alone.

CI in the tables represents the combination index. This is a parameter which reflects the presence or absence of synergism between two pharmacologically active agents. The calculation of the combination index is described by T.M. Brennan *et al* in Antiviral Research 1995, 173-187. The equation as used in the present

25 experiments was therefore

$$CI = \left(\frac{\text{concentration of drug (b)}}{IC_{50} \text{ of drug (b) alone}} \right) + \left(\frac{\text{concentration of IFN}}{IC_{50} \text{ of IFN alone}} \right)$$

30

If the CI is equal to 1 the two agents have a mutually additive effect. If the CI

-25-

is less than 1 they have a synergistic effect. If the CI is greater than 1 they have a mutually antagonistic effect. (M.C. Berenbaum in Pharmacol. Rev. 41, 93-141 (1989)).

Table 5: Mycophenolic acid (MPA) and IFN in Vero cells

Virus	IFN α 2 IC ₅₀ (IU/ml)	MPA IC ₅₀ (μ M)	CI	IFN α 8 IC ₅₀ (IU/ml)	MPA IC ₅₀ (μ M)	CI	IFN β IC ₅₀ (IU/ml)	MPA IC ₅₀ (μ M)	CI
Yellow fever	0.153	0	-	0.127	0	-	4.688	0	-
	0.076	0.275	0.695	0.076	0.184	0.731	1.376	1.388	0.96
	0.076	0.413	0.794	0.048	0.275	0.576	0	2.081	-
	0.048	0.619	0.757	0.048	0.413	0.675			
	0.048	0.928	0.980	0.048	0.619	0.822			
	0	1.388	-	0	1.388				
Dengue virus	0.489	0	-	0.489	0	-	4.688	0	-
	0.244	0.275	0.702	0.244	0.275	0.702	1.465	0.413	0.61
	0.153	0.413	0.610	0.076	0.413	0.453	1.465	0.619	0.758
	0.015	0.619	0.474	0.048	0.619	0.542	0.458	0.928	0.764
	0.015	0.928	0.697	0.016	0.928	0.699	0	1.388	-
	0	1.388	-	0	1.388	-			

Kunjin virus	0.092	0	-	0.092	0	-	0.916	0	-
	0.014	0.413	0.598	0.009	0.275	0.395	0.286	0.413	0.610
	0.009	0.619	0.767	0.009	0.413	0.544	0.090	0.619	0.542
	0	0.928	-	0.009	0.619	0.767	0.286	0.928	0.979
				0	0.928	-	0	1.388	-

Table 6: CPE-C and IFN in Vero cells

Virus	IFN α 2 IC ₅₀ (IU/ml)	CPE-C IC ₅₀ (μ M)	CI	IFN α 8 IC ₅₀ (IU/ml)	CPE-C IC ₅₀ (μ M)	CI	IFN β IC ₅₀ (IU/ml)	CPE-C IC ₅₀ (μ M)	CI
Yellow Fever	0.489	0	-	0.489	0	-	4.688	0	-
	0.153	0.017	0.513	0.153	0.017	0.513	1.465	0.025	0.513
	0.048	0.025	0.398	0.153	0.025	0.613	1.465	0.038	0.613
	0.048	0.038	0.548	0.048	0.038	0.548	0.458	0.056	0.531
	0.024	0.056	0.699	0.048	0.056	0.748	0.045	0.085	0.676
	0	0.085	-	0	0.085	-		0.127	-

Dengue virus	4.688	0	-	1.465	0	-	30	0	-
	0.229	0.142	0.144	0.458	0.017	0.345	2.930	0.285	0.231
	0.045	0.199	0.141	0.143	0.033	0.162	2.930	0.398	0.284
	0.045	0.279	0.197	0.045	0.067	0.159	0.916	0.558	0.291
	0.045	0.390	0.270	0.045	0.134	0.279	0.916	0.781	0.395
	0.045	0.547	0.374	0.045	0.268	0.535	0.286	1.093	0.519
	0.045	0.765	0.519	0	0.536	-	0.286	1.530	0.723
	0.045	1.071	0.724	0	0	-	0	2.142	-
	0	1.500	-	0	0	-	0	0	-
Kunjin virus	0.293	0	-	0.293	0	-	0.916	0	-
	0.092	0.025	0.450	0.092	0.025	0.404	0.286	0.025	0.402
	0.092	0.038	0.519	0.029	0.038	0.233	0.286	0.038	0.447
	0.029	0.056	0.394	0.029	0.056	0.293	0.090	0.056	0.292
	0.009	0.085	0.485	0.029	0.085	0.397	0.045	0.085	0.348
	0.009	0.127	0.713	0.029	0.127	0.547	0.090	0.127	0.546
	0	0.191	-	0.029	0.191	0.756	0	0.280	-
				0	0.286	-			

Table 7: 3-deazauridine (3-DAU) and IFN in Vero cells

Virus	IFN α 2 IC ₅₀ (IU/ml)	3-DAU IC ₅₀ (μ M)	CI	IFN α 8 IC ₅₀ (IU/ml)	3-DAU IC ₅₀ (μ M)	CI	IFN β IC ₅₀ (IU/ml)	3-DAU IC ₅₀ (μ M)	CI
Yellow Fever	0.489	0	-	0.245	0	-	1.465	0	-
	0.153	4.115	0.513	0.048	12.346	0.624	0.458	20.996	0.823
	0.077	12.346	0.757	0.015	20.576	0.776	0.143	29.394	0.812
	0	20.576	-	0	28.807	-	0	41.152	-

Table 8: 3-deazaneplanocin A (3-DAN) and IFN in Vero cells

Virus	IFN α 2 IC ₅₀ (IU/ml)	3-DAN IC ₅₀ (μ M)	CI	IFN α 8 IC ₅₀ (IU/ml)	3-DAN IC ₅₀ (μ M)	CI	IFN β IC ₅₀ (IU/ml)	3-DAN IC ₅₀ (μ M)	CI
Yellow fever	0.488	0	-	0.488	0	-	1.465	0	-
	0.015	0.725	0.395	0.076	0.725	0.416	0.143	0.725	0.462
	0.015	1.015	0.541	0.048	1.015	0.463	0.143	1.015	0.608
	0.015	1.420	0.745	0.015	1.420	0.541	0.143	1.420	0.812
	0	1.989	-	0	1.989	-	0	1.989	-
Dengue virus	1.465	0	-	1.465	0	-	9.375	0	-
	0.458	0.725	0.677	0.143	0.725	0.462	0.915	1.015	0.608
	0.143	1.015	0.608	0.045	1.015	0.541	0.089	1.420	0.724
	0.045	1.420	0.745	0.045	1.420	0.745	0	1.989	-
	0	1.989	-	0	1.989	-	0	1.989	-

Table 9: 6-azauridine (6-AU) and IFN in Vero cells

Virus	IFN $\alpha 2$ IC ₅₀ (IU/ml)	6-AU IC ₅₀ (μ M)	CI	IFN $\alpha 8$ IC ₅₀ (IU/ml)	6-AU IC ₅₀ (μ M)	CI	IFN β IC ₅₀ (IU/ml)	6-AU IC ₅₀ (μ M)	CI
Yellow fever	0.153	0	-	0.321	0	-	2.271	0	-
	0.048	1.224	0.811	0.153	0.816	0.762	1.465	0.816	0.931
	0.015	1.633	0.765	0.048	1.224	0.578	0.458	1.224	0.630
	0.015	2.041	0.932	0.048	1.633	0.721	0.458	1.633	0.773
	0	2.449	-	0.015	2.041	0.761	0.143	2.041	0.777
				0.048	2.449	1.007	0.458	2.449	1.059
				0	2.857	-	0	2.857	-

Table 10: NSC 382046 and IFN in Vero cells against Dengue virus

IFN α 2 IC ₅₀ (IU/ml)	NSC 382046 IC ₅₀ (μ M)	CI
4.688	0	-
1.465	0.095	0.758
0.045	0.141	0.672
0	0.212	-

10

Table 11: NSC 7364 and IFN in Vero cells against Dengue virus

IFN α 2 IC ₅₀ (IU/ml)	NSC 7364 IC ₅₀ (μ M)	CI	IFN α 8 IC ₅₀ (IU/ml)	NSC 7364 IC ₅₀ (μ M)	CI
1.465	0	-	4.688	0	-
0.733	0.186	0.834	1.465	0.372	0.813
0.458	0.372	0.979	0	0.743	-
0	0.558	-			

20

Table 12: NSC 143095 and IFN in Vero cells against yellow fever virus

IFN α 2 IC ₅₀ (IU/ml)	NSC 143095 IC ₅₀ (μ M)	CI	IFN α 8 IC ₅₀ (IU/ml)	NSC 143095 IC ₅₀ (μ M)	CI
0.458	0	-	0.153	0	-
0.143	0.848	0.756	0.048	0.386	0.813
0.045	1.272	0.763	0	0.772	-
0	1.907	-			

30

-33-

IFN β IC ₅₀ (IU/ml)	NSC 143095 IC ₅₀ (μ M)	CI
2.930	0	-
0.287	1.272	0.764
0	1.907	-

Table 13: Mycophenolic acid (MPA) and IFN α 8 in human cells against VSV and yellow fever virus

Virus	Cell type	IFN α 8 IC ₅₀ (IU/ml)	MPA IC ₅₀ (μ M)	CI
VSV	MRC 5	0	4.1	-
		4.9	0	-
		0.02	3.9	0.96
		0.01	2.6	0.64
		0.01	1.7	0.43
		0.21	1.2	0.33
		0.43	0.8	0.28
		1.22	0.5	0.37
		2.18	0.3	0.53
		4.39	0.2	0.95
		4.65	0.2	0.98
	HuH7	0	1.72	-
		2.06	0	-
		0.13	0.72	0.48
		0.38	0.48	0.46
		0.77	0.32	0.56

-34-

Yellow fever	HuH7	0	3.86	-
		7.85	0	-
		1.73	2.48	0.86
		1.94	1.65	0.68
		1.94	1.10	0.53
		1.22	0.73	0.35
		2.76	0.49	0.48
		6.99	0.33	0.97

Table 14: CPE-C and IFN in human cells against VSV and kunjin virus.

5

Cell type	Virus	IFN β IC ₅₀ (IU/ml)	CPE-C IC ₅₀ (μ M)	CI
HuH7	VSV	0	4.18	-
		35.7	0	-
		0.81	1.84	0.46
		0.81	1.23	0.32
		0.81	0.82	0.22
		1.08	0.55	0.16
		1.94	0.36	0.14
		2.59	0.24	0.13
	Kunjin	0	0.37	-
		2.59	0	-
		0.20	0.25	0.75
		0.23	0.17	0.54
		0.08	0.11	0.33
		0.81	0.07	0.51
		1.83	0.01	0.84

-35-

Cell type	Virus	IFN α 8 IC ₅₀ (IU/ml)	CPE-C IC ₅₀ (μ M)	CI
MRC-5	VSV	0	2.26	-
		3.10	0	-
		0.19	2.09	0.98
		0.61	1.39	0.81
		1.22	0.93	0.80
		2.45	0.41	0.97
		1.94	0.28	0.75
		2.18	0.18	0.79
		2.18	0.12	0.76
		2.18	0.08	0.74

Table 15: 3-deazaneplanocin A (3-DAN) and IFN in human cells against VSV

5

Cell type	3-DAN	IFN IC ₅₀ (IU/ml)		CI
		IFN α 8	IFN β	
MRC 5	0.172	0		-
	0	3.10		-
	0.115	0.38		0.79
	0.076	1.09		0.80
	0.051	1.94		0.92
	0.034	2.18		0.90
	0.023	2.18		0.84
	0.015	2.45		0.88
	0.010	2.45		0.85

-36-

HuH7	0.126		0	-
	0		19.80	-
	0.095		0.54	0.79
	0.064		0.54	0.54
	0.042		0.86	0.38
	0.028		1.22	0.29
	0.019		1.94	0.25
	0.013		2.18	0.21

Table 16: 6-azauridine (6-AU) and IFN β in human cells against VSV

5

Cell type	IFN β IC ₅₀ (IU/ml)	6-AU IC ₅₀ (μ M)	CI
MRC 5	0	80.8	-
	2.20	0	-
	0.38	25.3	0.49
	1.09	7.8	0.59
	1.22	2.4	0.59

10

15

-37-

Table 17: NSC 382046 and IFN β in human HuH7 cells against yellow fever and kunjin virus

Virus	IFN β	NSC 382046	CI
	IC ₅₀ (IU/ml)	IC ₅₀ (μ M)	
5 Yellow fever	0	0.350	-
	2.59	0	-
	0.81	0.192	0.86
	0.72	0.128	0.64
	0.57	0.085	0.46
	0.57	0.057	0.38
	0.57	0.038	0.33
	0.72	0.025	0.35
	0.81	0.017	0.36
	0.81	0.011	0.34
Kunjin virus	0	5.264	-
	18.74	0	-
	8.30	2.865	0.99
	11.10	1.910	0.96
	11.10	1.273	0.83
	11.10	0.849	0.75
	11.10	0.566	0.70

10

15

Table 18: NSC 143095 and IFN β in human HuH7 cells against yellow fever virus and VSV.

Virus	IFN β	NSC 143095	CI
	IC ₅₀ (IU/ml)	IC ₅₀ (μ M)	
5 VSV	0	11.822	-
	6.21	0.00	-
	0.08	6.448	0.56
	0.08	4.299	0.38
	0.25	2.866	0.28
	0.57	1.910	0.25
	1.83	1.274	0.40
	3.68	0.849	0.66
Yellow fever	0	0.510	-
	2.06	0.00	-
	0.08	0.340	0.71
	0.25	0.227	0.57
	0.81	0.151	0.69

-39-

Table 19: Tiazofurin and IFN β in human HuH7 cells against yellow fever virus and kunjin virus

Virus	IFN β IC ₅₀ (IU/ml)	Tiazofurin IC ₅₀ (μ M)	CI
5 Yellow fever	0	7.538	-
	0.37	0	-
	0.01	6.154	0.85
	0.05	4.103	0.68
	0.10	1.823	0.51
	0.28	0.812	0.87
Kunjin virus	0	6.923	-
	0.20	0	-
	0.01	4.615	0.73
	0.01	3.077	0.51
	0.02	2.051	0.38
	0.03	1.368	0.32
	0.04	0.912	0.33
	0.04	0.608	0.29
	0.08	0.405	0.46

10

15

-40-

Table 20: Selenofurin and IFN β in human HuH7 cells against yellow fever virus and kunjin virus

Virus	IFN β	Selenofurin	CI
	IC ₅₀ (IU/ml)	IC ₅₀ (μ M)	
5 Yellow fever	0	0.472	-
	0.43	0	-
	0.05	0.391	0.94
	0.04	0.261	0.65
	0.07	0.173	0.53
	0.16	0.117	0.62
	0.16	0.052	0.49
Kunjun virus	0	0.717	-
	0.20	0	-
	0.01	0.554	0.84
	0.01	0.369	0.58
	0.05	0.164	0.48
	0.05	0.109	0.40
	0.08	0.073	0.51
	0.08	0.049	0.47

10

15

-41-

Table 21: Amantadine and human IFN in human cells against VSV and kunjin virus

Cell Type	Virus	Amantadine IC ₅₀ (μM)	IFN IC ₅₀ (IU/ml)		CI
			IFN α8	IFN β	
5 MRC-5	VSV	913.8	0		-
		0	0.81		-
		584.9	0.12		0.79
		390.1	0.27		0.76
		259.9	0.27		0.62
		173.0	0.38		0.66
		115.8	0.61		0.87
HuH7	Kunjin virus	115.7		0	
		0		0.13	
		77		0.01	0.76
		51.3		0.04	0.76

Table 22: Neplanocin A and human IFN in human cells against VSV and Yellow Fever Virus

10

Cell Type	Virus	Neplanocin A IC ₅₀ (μM)	IFN IC ₅₀ (IU/ml)		CI
			IFN α8	IFN β	
MRC-5	VSV	2.9	0		-
		0	2.18		-
		2.2	0.04		0.80
		1.5	0.09		0.56
		1.0	0.12		0.40
		0.7	0.97		0.67
		0.4	1.22		0.71

-42-

HuH7	Yellow Fever	9.3		0	
		0		5.86	
		5.1		0.01	0.63
		3.4		0.04	0.71
		2.2		2.06	0.59

Example 3

5


By following the experimental procedure described in Examples 1 and 2 the compound NSC 184692 was found to have an ED_{50} against dengue virus of 120 pM in monkey Vero cells subjected to viral challenge by 100 $TCLD_{50}$ dengue virus. It was found that 100 pM of the compound enhanced the anti-viral effect of human

10 IFN β 10-fold.

CLAIMS

1. Use, in the manufacture of a medicament for the treatment of a
5 flavivirus or rhabdovirus infection, of:


- (a) an interferon, and
- (b) at least one compound selected from the group consisting of:
 - 5-membered cyclic nucleosides having the formula (I):



15


wherein $\sim X \sim$ is $=CH-$, $-CH_2-$ or $-O-$, Nu is selected from the group consisting of purines, pyrimidines and five- or six-membered aglycones, R_2 and R_3 are independently selected from the group consisting of H, OH, O-acyl, O-aryl and O-silyl, and R_1 is as defined for R_2 and R_3 or is O-phosphate, and
20 pharmaceutically acceptable metabolites, metabolite derivatives and salts thereof;

- mycophenolic acid compounds having the formula (II)




25 wherein R_4 is $-OR_6$ or $-N(R_7)R_8$ in which R_6 , R_7 and R_8 are independently selected from the group consisting of hydrogen and C_1-C_6 alkyl, and R_5 is
30 selected from the group consisting of hydrogen, phenyl and C_1-C_6 alkyl unsubstituted or substituted by a five- or six-membered saturated or

unsaturated heterocyclic ring, and pharmaceutically acceptable salts thereof;
 - imidazole derivatives represented by formula (III):




10 wherein R₉ is a hydrogen atom or



15

wherein R₁₀ is a hydrogen atom, C₁-C₆ alkyl, hydroxy(C₁-C₆ alkyl) or phenyl,
 R₁₁ and R₁₃ are independently selected from hydrogen and OR₁₂ and R₁₂ is a
 hydrogen atom or a hydroxy protecting group and A is CONH₂ or CN, and
 pharmaceutically acceptable salts thereof;
 20 - aminoadamantanes having the formula (IV):




25

wherein each of R₁₄, R₁₅, R₁₆ and R₁₇ is independently selected from the group
 consisting of H, F and CH₃ and X is N(R₁₈)₂, CH₂CH₂N(R₁₈)₂ or C(R₁₉)₂N(R₁₈)₂
 wherein each R₁₈ and R₁₉ is H, (C₁-C₆) alkyl, (C₆-C₁₀) aryl and (C₇-C₁₈)
 30 aralkyl; and

- 2,4-diaminopyrimidines having the formula (V):

-45-




5

wherein R₂₀

is phenyl substituted by one or more substituents selected from the group consisting of benzyl, NO₂, (C₁-C₆) alkylamino and halogen and R₂₁ is H or C₁-C₆ alkyl; or R₂₀ and R₂₁ form, together with the 2,4-diaminopyrimidine ring to which they are attached, a quinazoline derivative of formula (V'):

10



wherein Z is -CH₂NR₂₃- or -NR₂₃CH₂-; R₂₂, R₂₃ and R₂₄ are each, independently, H or C₁-C₆ alkyl; and n is 1 or 2, and pharmaceutically acceptable salts thereof.

2. Use of an interferon in the manufacture of a medicament for use with at least one compound (b) as defined in claim 1 in the treatment of a flavivirus or rhabdovirus infection.

3. Use of at least one compound (b) as defined in claim 1 in the manufacture of a medicament for use with an interferon in the treatment of a flavivirus or rhabdovirus infection.

20 4. Use according to any one of claims 1 to 3, wherein the flavivirus is selected from yellow fever virus, kunjin virus, dengue virus, hepatitis C virus, St. Louis encephalitis virus, Japanese encephalitis virus, Murray valley encephalitis virus and tick-borne encephalitis virus.

5. Use according to any one of claims 1 to 3 wherein the rhabdovirus is selected from vesicular stomatitis virus (VSV) and rabies virus.

25

6. Use according to any one of claims 1 to 3 wherein the interferon (a) is a human interferon.
7. Use according to any one of claims 1 to 3 wherein the interferon is selected from interferon $\alpha 2$, interferon $\alpha 8$ and interferon β .
- 5 8. Use according to claim 7, wherein the interferon is human interferon $\alpha 8$ having a specific activity of from 0.6×10^9 to 1.5×10^9 IU per mg protein.
9. Use according to claim 7, wherein the interferon is human interferon β having a specific activity of from 4×10^8 to 8×10^8 per mg protein.
- 10 10. Use according to any one of the preceding claims wherein the compound (b) is at least one compound selected from cyclopentenyl cytosine, mycophenolic acid, 5-ethynyl-1- β -D-ribofuranosylimidazole-4-carboxamide, amantadine hydrochloride, 3-deazaneplanocin, neplanocin A, 3-deazauridine, 6-azauridine, aristeromycin, pyrazofurin, tiazaforin, selenofurin, NSC 382046, NSC 7364, NSC 302325, NSC 184692D and NSC 382034.
- 15 11. Products containing an interferon and at least one compound (b) as defined in claim 1 as a combined preparation for simultaneous, separate or sequential use in treating a flavivirus or rhabdovirus infection.
12. Use, in the manufacture of a medicament for the treatment of a flavivirus or rhabdovirus infection, of an interferon $\alpha 8$ having a specific activity of
20 from 0.6×10^9 to 1.5×10^9 IU per mg protein.
13. Use according to claim 12, wherein the flavivirus is selected from yellow fever virus, kunjin virus, dengue virus, hepatitis C virus, St. Louis encephalitis virus, Japanese encephalitis virus, Murray valley encephalitis virus and tick-borne encephalitis virus.
- 25 14. Use according to claim 12, wherein the rhabdovirus is VSV.
15. Use according to claim 12, wherein the interferon $\alpha 8$ is human interferon $\alpha 8$.
16. Interferon $\alpha 8$ having a specific activity of from 0.6×10^9 to 1.5×10^9 IU per mg of protein for use in a method of treatment of the human or animal body by
30 therapy.
17. Interferon $\alpha 8$ according to claim 16 for use in the treatment of a

-47-

flavivirus or rhabdovirus infection.

18. Use of interferon $\alpha 8$ having a specific activity of from 0.6×10^9 to 1.5×10^9 IU per mg of protein in the manufacture of a medicament for use in the treatment of a flavivirus or rhabdovirus infection.

5 19. An anti-flavivirus or anti-rhabdovirus agent comprising interferon $\alpha 8$ having a specific activity of from 0.6×10^9 to 1.5×10^9 IU per mg of protein.

20. A method of treating a host having a flavivirus or rhabdovirus infection, which method comprises the step of administering to the host, in respective amounts which produce a synergistic ant Flaviviral or antirhabdoviral effect, an
10 interferon and at least one compound (b) as defined in claim 1.

21. An agent for use in the treatment of a flavivirus or rhabdovirus infection, which comprises an interferon and at least one compound (b) as defined in claim 1.

BLANK PAGE

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
31 August 2000 (31.08.2000)

PCT

(10) International Publication Number
WO 00/50064 A3

(51) International Patent Classification⁷: **A61K 38/21**,
A61P 31/14 // (A61K 38/21, 31:365) (A61K 38/21,
31:4164) (A61K 38/21, 31:517) (A61K 38/21, 31:13)
(A61K 38/21, 31:505) (A61K 38/21, 31:7052)

(21) International Application Number: PCT/US00/04699

(22) International Filing Date: 25 February 2000 (25.02.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/121,931 26 February 1999 (26.02.1999) US
60/181,068 8 February 2000 (08.02.2000) US

(74) Agent: WILSON, Mary, J.; Nixon & Vanderbye P.C.,
Suite 800, 1100 North Glebe Road, Arlington, VA 22201-
4714 (US).

(81) Designated States (*national*): AE, AL, AM, AT, AU, AZ,
BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE,
ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP,
KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD,
MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD,
SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ,
VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent
(AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent
(AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU,
MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM,
GA, GN, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (*for all designated States except US*): INSTI-
TUTE OF MOLECULAR AND CELL BIOLOGY
[SG/SG]; 30 Medical Drive, Singapore 117609 (SG).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): TAN, Yin, Hwee
[CA/SG]; 30 Medical Drive, Singapore 117609 (SG).
DRISCOLL, John, S. [US/US]; 4 Infield Court South,
Rockville, MD 20854 (US).

Published:

— With international search report.

(88) Date of publication of the international search report:
5 April 2001

*For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*

(54) Title: SYNERGISTIC COMBINATION FOR TREATMENT OF VIRAL-MEDIATED DISEASES

(57) Abstract: Flavivirus and rhabdovirus infections may be treated by administering an interferon such as interferon $\alpha 2$, interferon $\alpha 8$ or interferon β and at least one compound selected from 5-membered cyclic nucleosides, mycophenolic compounds, imidazole derivatives, aminoadamantanes and 2, 4-diaminopyrimidines.

WO 00/50064 A3

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 00/04699

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K38/21 A61P31/14 //(A61K38/21, 31:365), (A61K38/21, 31:4164), (A61K38/21, 31:517), (A61K38/21, 31:13), (A61K38/21, 31:505), (A61K38/21, 31:7052)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, BIOSIS, WPI Data, PAJ, MEDLINE, CHEM ABS Data, EMBASE, SCISEARCH

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5 676 942 A (TESTA DOUGLAS ET AL) 14 October 1997 (1997-10-14)	1-11,20, 21
Y	the whole document, especially column 5 line 24-line 47	1-11,20, 21
Y	NEYTS J ET AL: "Use of the yellow fever virus vaccine strain 17D for the study of strategies for the treatment of yellow fever virus infections." ANTIVIRAL RESEARCH, vol. 30, no. 2-3, 1996, pages 125-132, XP000946359 ISSN: 0166-3542 the whole document	1-11,20, 21

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *S* document member of the same patent family

Date of the actual completion of the international search

14 December 2000

Date of mailing of the international search report

03. 01. 2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Stein, A

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 00/04699

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 5 380 879 A (SJOGREN ERIC B) 10 January 1995 (1995-01-10) cited in the application the whole document	1-11,20, 21
Y	ANDREI G. ET AL: "Molecular approaches for the treatment of hemorrhagic fever virus infections." ANTIVIRAL RESEARCH; (1993) 22/1 (45-75). , XP000971421 the whole document, especially page 53 line 25-page 63 line 19	1-11,20, 21
Y	HOLY A ET AL: "STRUCTURE-ACTIVITY STUDIES ON OPEN-CHAIN ANALOGUES OF NUCLEOSIDES: INHIBITION OF S-ADENOSYL-L-HOMOCYSTEINE HYDROLASE AND ANTIVIRAL ACTIVITY. 1.NEUTRAL OPEN-CHAIN ANALOGUES" COLLECTION OF CZECHOSLOVAK CHEMICAL COMMUNICATIONS, ACADEMIC PRESS, LONDON, GB, vol. 50, 1985, pages 245-261, XP000960342 ISSN: 0010-0765 the whole document	1-11,20, 21
Y	ARROYO J I ET AL: "EFFECT OF HUMAN GAMMA INTERFERON ON YELLOW FEVER VIRUS INFECTION" AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, vol. 38, no. 3, 1988, pages 647-650, XP000946332 ISSN: 0002-9637 the whole document	1-11,20, 21
Y	DE CLERCQ E ET AL: "ANTIVIRAL ACTIVITIES OF 5-ETHYNYL-1-BETA-D-RIBOFURANOSYLIMIDAZOLE- 4-CARBOXAMIDE AND RELATED COMPOUNDS" ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, vol. 35, no. 4, 1991, pages 679-684, XP000971464 ISSN: 0066-4804 the whole document	1-11,20, 21
X	WO 98 19670 A (NAJARIAN THOMAS) 14 May 1998 (1998-05-14) the whole document, especially page 6 line 5-line 20	1-11,20, 21
A	US 4 975 434 A (MARQUEZ VICTOR E ET AL) 4 December 1990 (1990-12-04) cited in the application the whole document	1-11,20, 21

-/-

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 00/04699

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	DRISCOLL J S ET AL: "CYCLOPENTENYL CYTOSINE A NEPLANOCIN ANALOGUE WITH PRECLINICAL ANTITUMOR AND ANTIVIRAL ACTIVITY" PROCEEDINGS AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING, vol. 28, 1987, page 328 XP000946357 ISSN: 0197-016X the whole document	1-11,20, 21
A	FOSTER G R ET AL: "DIFFERENT RELATIVE ACTIVITIES OF HUMAN CELL-DERIVED INTERFERON- ALPHA SUBTYPES: IFN-ALPHA8 HAS VERY HIGH ANTIVIRAL POTENCY" JOURNAL OF INTERFERON AND CYTOKINE RESEARCH,US,MARY ANN LIEBERT, NEW YORK, NY, vol. 16, no. 12, 1996, pages 1027-1033, XP000876621 ISSN: 1079-9907 the whole document	1-11,20, 21
A	EP 0 331 080 A (YAMASA SHOYU KK ;SUMITOMO PHARMA (JP)) 6 September 1989 (1989-09-06) cited in the application the whole document	1-11,20, 21
A	GB 1 135 898 A (DAVOLL JOHN) 4 December 1968 (1968-12-04) the whole document	1-11,20, 21
A	HYNES JB ET AL: "Quinazolines as inhibitors of dihydrofolate reductase. 4. Classical analogues of folic and isofolic acids" JOURNAL OF MEDICINAL CHEMISTRY, vol. 20, no. 4, 1977, pages 588-591, XP002155519 the whole document	1-11,20, 21
E	WO 00 15210 A (KWONG ANN ;VERTEX PHARMA (US); TUNG ROGER (US)) 23 March 2000 (2000-03-23) the whole document	1-11,20, 21

-/-

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 00/04699

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>J A FINDOR ET AL: "AMANTADINE HCL ALONE AND ASSOCIATED WITH RECOMBINANT ALPHA IFN 2a DURING A SHORT TERM THERAPY IN CHRONIC HCV INFECTION" HEPATOLOGY,US,WILLIAMS AND WILKINS, BALTIMORE, MD, vol. 26, no. 4, 1 October 1997 (1997-10-01), page 217A XP002093941 ISSN: 0270-9139 the whole document</p>	
A	<p>LUSCRI B J: "SYNERGISTIC EFFECTS OF HUMAN INTERFERONS WITH EITHER AMANTADINE OR RIMANTADINE" ABSTRACTS OF THE ANNUAL MEETING OF THE AMERICAN SOCIETY FOR, vol. 83, 1983, page A130 XP000946512 1983 ISSN: 0094-8519 the whole document</p>	

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US 00/04699

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Although claims 20 and 21 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☒ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
1-11, 20,21 (all partially)
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☒ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 1-11,20,21 partially

Antiviral composition comprising interferon in combination with 5-membered cyclic nucleosides for the treatment of flavivirus and rhabdovirus infection.

2. Claims: 1-11,20,21 partially

Antiviral composition comprising interferon in combination with mycophenolic acid for the treatment of flavivirus and rhabdovirus infection.

3. Claims: 1-11,20,21 partially

Antiviral composition comprising interferon in combination with imidazole derivatives for the treatment of flavivirus and rhabdovirus infection.

4. Claims: 1-11,20,21 partially

Antiviral composition comprising interferon in combination with adamantanes for the treatment of flavivirus and rhabdovirus infection.

5. Claims: 1-11,20,21 partially

Antiviral composition comprising interferon in combination with quinazoline derivatives of 2,4-diaminopyrimidine for the treatment of flavivirus and rhabdovirus infection.

6. Claims: 12-19

Interferon alpha8 for the treatment of flavivirus and rhabdovirus infection.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 00/04699

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5676942 A	14-10-1997	US 5503828 A AT 179330 T AU 674306 B AU 3660093 A CA 2129533 A DE 69324671 D EP 0625991 A JP 7503851 T KR 223255 B PL 176408 B RU 2129437 C WO 9316107 A	02-04-1996 15-05-1999 19-12-1996 03-09-1993 19-08-1993 02-06-1999 30-11-1994 27-04-1995 15-10-1999 31-05-1999 27-04-1999 19-08-1993
US 5380879 A	10-01-1995	AU 1916995 A BR 9506820 A CA 2183529 A CN 1143366 A EP 0745074 A FI 963219 A IL 112664 A JP 9509171 T WO 9522535 A US 5441953 A ZA 9501292 A	04-09-1995 09-09-1997 24-08-1995 19-02-1997 04-12-1996 11-10-1996 20-06-1999 16-09-1997 24-08-1995 15-08-1995 16-08-1996
WO 9819670 A	14-05-1998	AU 5157998 A	29-05-1998
US 4975434 A	04-12-1990	AU 5097790 A WO 9009177 A US 4968690 A	05-09-1990 23-08-1990 06-11-1990
EP 0331080 A	06-09-1989	JP 1221388 A JP 1930254 C JP 6060193 B JP 1254697 A JP 2565736 B JP 1254698 A JP 2514830 B CA 1317588 A US 5059590 A US 5126361 A	04-09-1989 12-05-1995 10-08-1994 11-10-1989 18-12-1996 11-10-1989 10-07-1996 11-05-1993 22-10-1991 30-06-1992
GB 1135898 A		NONE	
WO 0015210 A	23-03-2000	AU 6037499 A	03-04-2000